Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who have very little alternative treatment options that are both safe and efficacious. Unlike in the case of bedaquiline, pretomanid might become affordable. The anti-tuberculosis drug … Continue reading Pretomanid: XDR-TB may soon become easily treatable
Pretomanid
Explainer: What makes the new drug-resistant TB medicine Pretomanid promising
When used in combination with bedaquiline and linezolid, the newly approved pretomanid drug for MDR-TB and XDR-TB had an overall treatment success rate of about 90%. Besides better effectiveness, the duration of treatment is just six months. Treating drug-resistant tuberculosis — multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) — got a shot in the … Continue reading Explainer: What makes the new drug-resistant TB medicine Pretomanid promising
Science Chronicle 